Charles Wolfus
Chief Tech/Sci/R&D Officer presso ALECTOR, INC.
Posizioni attive di Charles Wolfus
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ALECTOR, INC. | Chief Tech/Sci/R&D Officer | 01/01/2019 | - |
Storia della carriera di Charles Wolfus
Precedenti posizioni note di Charles Wolfus
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| MYOKARDIA, INC. | Corporate Officer/Principal | 01/09/2014 | 01/01/2019 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01/01/2011 | 01/01/2014 |
Formazione di Charles Wolfus
| University of California San Diego | Undergraduate Degree |
| California Western School of Law | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ALECTOR, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Charles Wolfus
- Esperienza
